The sale of the ophthalmology business alone could earn the company around $5 billion, according to the report. Private equity firms are already studying the business.
Negotiations are ongoing, and if a sale happens it will likely happen in 2023, Bloomberg reported.
In 2019, Novartis spun-off its Alcon eyecare business. In August, it spun-off its generic-drugs unit.
